^
Association details:
| Biomarker: | FLT3 F691L |
|---|---|
| Cancer: | Acute Myelogenous Leukemia |
| Drug: | sunitinib (c-KIT inhibitor, VEGFR inhibitor, PDGFR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Emergence of polyclonal FLT3 tyrosine kinase domain mutations during sequential therapy with sorafenib and sunitinib in FLT3-ITD-positive acute myeloid leukemia
Excerpt:
Sunitinib suppressed leukemic clones with D835H and F691L mutations, but not D835Y. Cells expressing sorafenib-resistant FLT3 mutations were sensitive to sunitinib in vitro.
DOI:
https://dx.doi.org/10.1158%2F1078-0432.CCR-13-1323
